Transfusion medicine

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020

Friday, August 7, 2020 - 2:23pm

Because of the ongoing pandemic, the conference has been rescheduled to take place from August 11-13, 2020 and will be held virtually.

Key Points: 
  • Because of the ongoing pandemic, the conference has been rescheduled to take place from August 11-13, 2020 and will be held virtually.
  • Dr. Chirag Shah is Vice President Research and Development Engineering and Quality Systems at Arch Therapeutics.
  • Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.
  • The mission of SAGES is to improve quality patient care through education, research, innovation and leadership, principally in gastrointestinal and endoscopic surgery.

Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch

Friday, August 7, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.
  • We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.
  • The INTERCEPT Blood System for platelets and plasma provides a proactive approach to reduce the risk of transfusion-transmitted infectious disease (TTID).
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Haemonetics Clinical Study Results On A New, Personalized Approach To Plasma Collection To Be Presented At 2020 AABB Annual Meeting

Friday, August 7, 2020 - 11:45am

The IMPACT study, one of the largest clinical trials on the topic of plasmapheresis, was designed to test a novel, personalized approach to plasma collection using the NexSys PCS Plasma Collection System.

Key Points: 
  • The IMPACT study, one of the largest clinical trials on the topic of plasmapheresis, was designed to test a novel, personalized approach to plasma collection using the NexSys PCS Plasma Collection System.
  • The IMPACT study was a multicenter, prospective, double-blinded, randomized controlled clinical trial involving 3,443 donors who underwent 23,137 plasma donations.
  • The number of repeat donations was not impacted and increasing collection volume up to 1,000 mL was well tolerated.
  • "At a time when the world needs more plasma, this trial shows the value of a personalized approach."

Global HLA Typing Industry, Forecast to 2026 - Featuring Thermo Fisher Scientific, Omixon, CareDx, and QIAGEN Amongst Others

Thursday, August 6, 2020 - 9:45pm

The global HLA typing market is expected to reach USD 990.12 million by 2026 from USD 659.75 million in 2020, rising at a CAGR of ~7%.

Key Points: 
  • The global HLA typing market is expected to reach USD 990.12 million by 2026 from USD 659.75 million in 2020, rising at a CAGR of ~7%.
  • Majorly the increase in certain diseases such as blood cancers, genetic blood disorders where stem cell transplantation is required, this situation is expected to drive the HLA Typing market.
  • The global HLA (Human Leukocyte Antigen) Typing market is segmented based on end-user.
  • Globally, the HLA Typing market is growing at a CAGR of ~7.0% during the forecast period of 2020-2026.

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

Thursday, August 6, 2020 - 5:01pm

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.

Key Points: 
  • BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.
  • Plasma is a lifeline for thousands of people with rare, chronic and complex diseases, and we are excited to open the first BioLife plasma collection center in Louisiana.
  • To learn more about BioLife Plasma Services, the donation process, and to schedule an appointment, please visit the BioLife website.
  • BioLife Plasma Services is an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies.

Haemonetics First Quarter Fiscal 2021 Earnings Release Available on Investor Relations Website

Tuesday, August 4, 2020 - 11:00am

The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.

Key Points: 
  • The Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8 a.m. EDT August 4, 2020.
  • The call can be accessed with the following information:
    U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
    Conference ID required for access: 3897757
    A live webcast of the call can be accessed on Haemonetics' Investor Relations website.
  • Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.
  • To learn more about Haemonetics, visit our website at http://www.haemonetics.com .

Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020 - ResearchAndMarkets.com

Tuesday, August 4, 2020 - 10:00am

The "Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Tranexamic acid.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Tranexamic acid market trends and forecast, distinguish Tranexamic acid manufacturers and suppliers.

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Saturday, August 1, 2020 - 4:00pm

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.
  • These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.
  • We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.
  • Our experience as leaders in hematology means we are well prepared to meet todays needs as we pursue future developments in the treatment of bleeding disorders.

The Blood Connection at Forefront of COVID-19 Fight

Friday, July 31, 2020 - 6:40pm

The Blood Connection (TBC) has been at the forefront of local convalescent plasma collection efforts for several months, in its commitment to meet every patients need.

Key Points: 
  • The Blood Connection (TBC) has been at the forefront of local convalescent plasma collection efforts for several months, in its commitment to meet every patients need.
  • Rarely is the blood collection community highlighted by nation leadership, but because of blood centers essential role in collecting convalescent plasma, TBCs work is now part of a public health initiative.
  • TBC belongs to a network of local blood centers, called Americas Blood Centers (ABC), who supply 60 percent of the national blood supply.
  • We are incredibly grateful to The Blood Connection for their commitment to our South Carolina patients and community.

eTrueNorth Actively Participating in “The Fight Is In Us” Campaign Encouraging COVID-19 Survivors to Donate Plasma

Friday, July 31, 2020 - 3:49pm

This broad-based national campaign will encourage all individuals who have recovered from COVID-19 to donate plasma that may help others diagnosed with the virus.

Key Points: 
  • This broad-based national campaign will encourage all individuals who have recovered from COVID-19 to donate plasma that may help others diagnosed with the virus.
  • A COVID-19 survivors convalescent plasma may be transfused into patients struggling against the virus or used to develop another potential treatment.
  • eTrueNorth will be asking those who have had a positive test result from one of the drive-through specimen collection sites to consider donating plasma by visiting https://thefightisinus.org/.
  • By partnering with national pharmacy brands, eTrueNorth takes full advantage of its Voucher Solution to make testing available to those in need.